Skip to main content
Category

News

BullFrog

BullFrog AI and Lieber Institute for Brain Development Reveal New Insights into Bipolar Disorder Pathways and Potential Drug Targets

By News

BullFrogGAITHERSBURG, Md., July 25, 2024 (GLOBE NEWSWIRE) — BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a leader in AI-driven drug discovery, announced significant advancements in its ongoing collaboration with the Lieber Institute for Brain Development (LIBD). Building on the progress detailed in our May 16, 2024 release, our research has now pinpointed specific molecular pathways associated with bipolar disorder (BD), enabling the identification of new candidate drug targets.

Read More
Georgiamune

Georgiamune Announces First Patient Dosed in A First-In-Class Phase 1 Cancer Treatment Trial of GIM-531

By News

GeorgiamuneGAITHERSBURG, Md., July 30, 2024 (GLOBE NEWSWIRE) — Today, Georgiamune Inc., a privately held, clinical-stage biotechnology company, announced that the first patient has been dosed with GIM-531 in a first-in-human, phase 1 clinical trial for the treatment of advanced cancer patients. GIM-531 development focuses on indications that are currently not addressed with existing or available immunotherapies including anti-PD-1 antibodies. It is an oral therapy that is a first-in-class selective T regulatory cell inhibitor.

Read More
Emergent

Emergent BioSolutions Completes Sale of RSDL® (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million

By News

EmergentGAITHERSBURG, Md., July 31, 2024 (GLOBE NEWSWIRE) — Today, Emergent BioSolutions Inc. (NYSE: EBS) announced the sale of RSDL® (Reactive Skin Decontamination Lotion) kit to SERB Pharmaceuticals, a global pharmaceutical company, for a purchase price of approximately $75 million. In addition, SERB will pay Emergent a $5 million payment upon achievement of a milestone related to the sourcing of a certain component of RSDL®. The transaction has signed and closed simultaneously. 

In addition, SERB will acquire and maintain operations of Emergent’s leased manufacturing facility in Hattiesburg, Mississippi, and several site-based employees who support RSDL® will join SERB. SERB will also acquire the RSDL® product inventory as part of the transaction and will assume certain related contracts. Emergent’s Winnipeg facility will continue to manufacture and supply bulk lotion to SERB under a long-term supply agreement between the two companies.

Read More
MoCo

Montgomery County Council Approves Great Seneca Plan: Connecting Life and Science

By News

MoCoROCKVILLE, Md., July 30, 2024The Montgomery County Council voted today to approve the Planning Board Draft of the Great Seneca Plan: Connecting Life and Science with revisions. The plan covers 4,330 acres located in the heart of the I-270 Corridor between the cities of Gaithersburg and Rockville and the town of Washington Grove. The Plan makes recommendations to strengthen the economic competitiveness of the Life Sciences Center, guide future developments, and transform public spaces and amenities in the area to provide valuable links and social spaces. 

“The Great Seneca Science Corridor is one of Montgomery County’s most important strategic areas, as the heart of our globally recognized biohealth industry with world-class research, education, and health care facilities,” said Council President Andrew Friedson who also chairs the Planning, Housing and Parks (PHP) Committee. “This plan builds on that strength by creating a more sustainable and vibrant community with greater connectivity to improve quality of life and economic competitiveness.”

Read More
METROMoCo

WBJ: Metro, Montgomery County partner for major North Bethesda development

By News

METROMoCoBy Dan Brendel – Staff Reporter, Washington Business Journal -Jul 29, 2024 – Montgomery County and Metro have announced a formal partnership and preliminary developer solicitation to pave the way for up to 3.7 million square feet of life science-focused mixed-used development in North Bethesda, the economic development apple of Montgomery County’s eye.

The county and transit authority signed a memorandum of understanding and announced a request for qualifications on Monday, beginning the hunt for a development partner to build a University of Maryland-anchored project, integrated with a new North Bethesda Metro station entrance, on 14 noncontiguous acres of vacant Metro-owned land at the southeast corner of Rockville Pike and Old Georgetown Road.

Read More
Tonix

Frederick’s Tonix Pharmaceuticals Awarded Up to $34 Million U.S. Department of Defense Contract for Accelerated Development of Broad-Spectrum Antiviral Program

By News

TonixFREDERICK, Md.July 29, 2024 /PRNewswire-PRWeb/ — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced it has been awarded an Other Transaction Agreement (OTA) with a potential for up to $34 million over five years by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense (DoD). The objective of the contract is to develop small molecule broad-spectrum antiviral agents for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments.

TedcoAzadi

TEDCO Invests in Azadi Health

By News

TedcoAzadiCOLUMBIA, Md., (July 29, 2024) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $100,000 Pre-Seed Builder Fund investment in Azadi Health. TEDCO’s Pre-Seed Builder Fund is housed under TEDCO’s Social Impact Funds which were created to engage and invest in economically underserved founders and communities.

Read More
SolaxaTedcoBHI

BioHealth Innovation Celebrates Solaxa Inc.’s Recent TEDCO Investment

By News

SolaxaTedcoBHIBioHealth Innovation, Inc. (BHI) proudly recognizes the $500,000 investment from TEDCO in Solaxa Inc., a Bethesda-based biopharmaceutical company. Led by Founder & CEO Christian Walker, Solaxa is a clinical-stage biopharmaceutical company developing a portfolio of aminopyridine drugs that both detect and treat ion channel dysfunction. Previous research has shown that aminopyridines can improve nerve signaling and muscle function in patients with Multiple Sclerosis, and Solaxa is presently researching additional benefits in patients with other nerve disorders. Solaxa is organized as a for-profit public benefit corporation, with a mission to advance scientific knowledge and deliver impactful and accessible therapies that improve outcomes for patients worldwide.   

Prior to this investment from TEDCO, Solaxa was recognized as the “Best of Montgomery” finalist at the 7th Annual BioHealth Capital Region Crab Trap Pitch Competition in September 2023. Even more recently, Solaxa was recognized as “Venture of the Year” by the Maryland Tech Council in May 2024.  

Read More
Alex P and Rich 250 x 600 px

BioHealth Capital Region Maintains #3 Ranking: Insights with GEN’s Alex Philippidis on BioTalk

By News

 

Alex P and Rich 250 x 600 pxIn this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., speaks with Alex Philippidis, Senior Business Editor at Genetic Engineering & Biotechnology News. Alex joins the podcast to discuss the latest Top 10 U.S. Biopharma Clusters list, where the BioHealth Capital Region secured its #3 ranking for the second consecutive year.

The conversation highlights the factors that contributed to the success of the top biopharma clusters, focusing on early investments in biotech, the generation of high-quality science, building networks with partners, and broadening clusters beyond anchor businesses. Alex elaborates on how these regions have sustained their scientific excellence and the long-lasting impact of pioneering efforts.

Listening now on your favorite podcast platforms:
Apple: https://apple.co/4bYl81G 
Spotify: https://spoti.fi/3zVLIuU
Amazon Music: https://amzn.to/4d6dBiQ
TuneIn:https://bit.ly/4fBDs3R

Read More
Jlabs 2024 250

BioBuzz: Growth of Early-Stage Resident Companies Marks the Third Anniversary of Johnson & Johnson Innovation – JLABS @ Washington, DC

By News

Jlabs 2024 250In celebration of the three-year anniversary of JLABS @ Washington, DC (JLABS DC), it’s great timing to highlight recent accomplishments and milestones reached by incubating and regional companies. Additionally, JLABS DC is excited to share new access to specialized lab equipment to support more innovators within the region. 

Since the start of 2024, there has been continued success for incubating companies that reside at JLABS DC. Examples with recent funding announcements include Nanochon, raising $4 million in a Series Seed Prime, Acclinate closing $7 million in a Series A round, and Tiny Cargo securing investment from Virginia Ventures Partners. 

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.